Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1504.3.

https://doi.org/10.1182/blood-2024-205101

Published: 2024

Journal Articles

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Mikkael A. Sekeres, Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Maria Diez-Campelo, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcarcel, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Esther Natalie Oliva

Blood (2024) 144 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2024-199636

Published: 2024

Journal Articles

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Blood (2024) 144 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2024-204693

Published: 2024

Journal Articles

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Blood (2024) 144 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2024-204659

Published: 2024

Journal Articles

Clinician's Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

Esther Natalie Oliva, Fabio Efficace, Maria Rosa Valvano, Paola Arcuri, Roberta Battistini, Elisa Buzzatti, Cristina Clissa, Cristina Danesin, Alessia Salemme, Francesco Sparano, Federico Chiurazzi

Blood (2024) 144 (Supplement 1): 2440.

https://doi.org/10.1182/blood-2024-205336

Published: 2024

Journal Articles

Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher G. Pelligra, Shien Guo, Aylin Yucel, Mrudula B. Glassberg, Laurie Eliason, Ahmed Hnoosh, Dimana Miteva, Shelo Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2024-198374

Published: 2024

Journal Articles

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Blood (2024) 144 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2024-200885

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Patient-Reported Outcomes in Myeloproliferative Neoplasms: A Systematic Review

Esther Natalie Oliva, Julia Schroer, Tatyana Ionova, Edward Laane, Sam Salek, Ina Monsef, Nicole Skoetz, Mario Csenar

Blood (2024) 144 (Supplement 1): 7927.

https://doi.org/10.1182/blood-2024-210724

Published: 2024

Journal Articles

Luspatercept for the Treatment of Transfusion-Dependent Anemia in Patients with Myelodysplastic Neoplasms with del5q, Refractory/Resistant/Intolerant to Prior Treatments (QOL-ONE Phoenix)

Esther Natalie Oliva, Antonella Poloni, Chiara Frairia, Marta Riva, Isabella Capodanno, Ilaria Maria Delfino, Maria Grazia D'Errigo, Corrado Mammì, Giuseppe Ianni', Gina Zini, Davide Griguolo, Monia Marchetti, Carmelo Gurnari, Maria Teresa Voso, Bruno Fattizzo

Blood (2024) 144 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2024-205325

Published: 2024

Journal Articles

Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3 -ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial

Esther Natalie Oliva, Sudhir Unni, Francesco Cottone, Rohan Vashi, Xiaocong Li, Jorge Cortes, Mikkael A. Sekeres

Blood (2023) 142 (Supplement 1): 918.

https://doi.org/10.1182/blood-2023-189035

Published: 2023

Journal Articles

Net Clinical and Quality of Life Benefit of Luspatercept in Transfusion-Dependent MDS: A Win Ratio Analysis Using Data from the Phase 3 MEDALIST Study

Esther Natalie Oliva, Christopher Pelligra, Jennifer Lord-Bessen, Shien Guo, Jan Sieluk, Mrudula B. Glassberg, Dimana Miteva, Aylin Yucel

Blood (2023) 142 (Supplement 1): 6467.

https://doi.org/10.1182/blood-2023-173368

Published: 2023

Journal Articles

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Valeria Santini, Rami S. Komrokji, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Karen L. Keeperman, Shelonitda Rose, Ana Carolina Giuseppi, Valerie Vilmont, Yinzhi Lai, Dimana Miteva, Barkha Aggarwal, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 915.

https://doi.org/10.1182/blood-2023-178546

Published: 2023

Journal Articles

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher Pelligra, Shien Guo, Jennifer Lord-Bessen, Hong Xiao, Aylin Yucel, Dimana Miteva, Shelonitda Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2023-174660

Published: 2023

Journal Articles

Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment

Blood (2023) 142 (Supplement 1): 6046.

https://doi.org/10.1182/blood-2023-186325

Published: 2023

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Differences in Experiences Reported By Patients with Acute and Chronic Leukemia: A Global Survey

Zack Pemberton-Whiteley, Samantha Nier, Jan Geissler, Sophie Wintrich, Anne-Pierre Pickaert, Sam Salek, Esther Natalie Oliva, Tatiana I. Ionova, Jennie Bradley

Blood (2022) 140 (Supplement 1): 13273–13275.

https://doi.org/10.1182/blood-2022-163466

Published: 2022

Journal Articles

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Dimana Miteva, Pierre Fenaux

Blood (2022) 140 (Supplement 1): 6971–6973.

https://doi.org/10.1182/blood-2022-157487

Published: 2022

Journal Articles

Experiences and Views of Leukemia Patients: A Global Survey

Zack Pemberton-Whiteley, Samantha Nier, Nick York, Deborah Baker, Michael Rynne, Nicole Schroeter, Denis Costello, Lidija Pecova, Esther Natalie Oliva, Tatiana I. Ionova, Sam Salek, Jennie Bradley

Blood (2022) 140 (Supplement 1): 5258–5259.

https://doi.org/10.1182/blood-2022-163309

Published: 2022

Journal Articles

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Valeria Santini, Pierre Fenaux, Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Esther Natalie Oliva, Xianwei Ha, Dimana Miteva, Aylin Yucel, Jose Alberto Nadal, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4079–4081.

https://doi.org/10.1182/blood-2022-157489

Published: 2022

NARROW

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Clinician's Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Patient-Reported Outcomes in Myeloproliferative Neoplasms: A Systematic Review

Luspatercept for the Treatment of Transfusion-Dependent Anemia in Patients with Myelodysplastic Neoplasms with del5q, Refractory/Resistant/Intolerant to Prior Treatments (QOL-ONE Phoenix)

Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3 -ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial

Net Clinical and Quality of Life Benefit of Luspatercept in Transfusion-Dependent MDS: A Win Ratio Analysis Using Data from the Phase 3 MEDALIST Study

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Differences in Experiences Reported By Patients with Acute and Chronic Leukemia: A Global Survey

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Experiences and Views of Leukemia Patients: A Global Survey

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only